Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis

descriptionPublicationkeyboard_double_arrow_right Article 28 Oct 2020Publisher:Publishing House OKIJournal:Kachestvennaya klinicheskaya praktika (issn: 2588-0519, eissn: 2618-8473,

Copyright policy )

Authors: V. M. Tsvetov; I. N. Sychev; D. A. Sychev;

doi: 10.37489/2588-0519-2020-s4-39-46

Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis

- Summary
- Subjects
- Metrics

Abstract

Impaired kidney function may influence pharmacokinetics of most of the drugs, including the ones used in COVID-19. In this publication, the most important pharmacokinetic parameters and dose adjustment approaches are provided, based on The Renal Drug Handbook и Sanford Guide. In the majority of cases, mild kidney function reduction does not necessitate dose adjustment. Each case should be considered individually, measuring benefits against risks.

Keywords

RS1-441, Pharmacy and materia medica, covid-19, диализ, Medical technology, коронавирус, хроническая почечная недостаточность, R855-855.5

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average